Effects of Suvorexant on the Insomnia Severity Index in Patients with Insomnia: Analysis of Pooled Phase 3 Data

Suvorexant is an orexin receptor antagonist that is approved in the US, Japan and Australia for the treatment of insomnia. Using outcomes from the Insomnia Severity Index (ISI) in the core registration studies, we explored suvorexant effects on sleep problems and their impact on daytime function.

https://www.sleep-journal.com/article/S1389-9457(18)30248-X/fulltext?rss=yes

Source: Sleep Medicine - October 1, 2018 Category: Sleep Medicine Authors: W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, Charles M. Morin, Christopher Lines, David Michelson Tags: Original Article Source Type: research